The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

Successful surgery for head and neck squamous cell carcinoma (HNSCC) relies upon complete tumor removal and safe preservation of the fragile nerves in the vicinity. Both are challenging. Fluorescence ...

As stated in the study published in Cancer Communications, head and neck squamous cell carcinoma (HNSCC ... It destroys the ...

Tongue cancer is a type of cancer that starts in the cells of the tongue, and can cause lesions or tumors on your tongue ... “oropharyngeal cancer.” Squamous cell carcinoma is the most ...

This exposure increases the risk of malignancies like squamous cell carcinoma. Additionally, biological agents contribute to head and neck cancer (HNC) incidence, such as oropharyngeal squamous ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

Application error: a client-side exception has occurred (see the browser console for more information).

For the most mature data set, the single arm cohort previously presented at AACR 2023, as of a July 5, 2024 data cutoff, for all 54 patients, the median DOR, PFS and OS were 6.7, 5.1, and 12.0 months, ...

About Cutaneous Squamous Cell Carcinoma Cutaneous squamous cell carcinoma ("cSCC") is the second ... cSCC causes significant functional morbidities and cosmetic deformities based on tumors commonly ...